Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study.
Akihiro MorishitaKyoko OuraKei TakumaMai NakaharaTomoko TadokoroKoji FujitaJoji TaniTingting ShiTakashi HimotoMiwa TatsutaAkio MoriyaTomonori SenooAkemi TsutsuiTakuya NaganoKoichi TakaguchiMasafumi OnoTsutomu MasakiPublished in: Hepatology international (2022)
Pemafibrate improved LFTs, including fibrotic biomarkers and FAST score, due to the hepatic anti-inflammatory effect, suggesting that pemafibrate may prevent disease progression in NAFLD patients with hypertriglyceridemia.